NCT05480865
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation
Registry record
- Lead sponsor
- Navire Pharma Inc., a BridgeBio company
- Conditions
- Solid Tumor, Adult; Metastatic Solid Tumor; Metastatic NSCLC; Non Small Cell Lung Cancer
- Primary completion
- Aug 22, 2024Actual
- Completion
- Locked
- Start
- Locked
- Enrollment
- Locked
- Interventions
- Locked
- Study type
- Locked
- Results on the registry
- Locked
- Record last updated
- Locked
Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerRecorded changes
0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.
Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.